Centene's Q1 health benefits ratio improves sharply, but cautious full-year outlook limits guidance boost

Centene Corporation (CNC) reported a strong rebound in Q1 2026, with its health benefits ratio (HBR) improving significantly to 87.3% from 94.3% in Q4 2025. This improvement was driven by Medicaid rate increases, better medical cost management, and a mild flu season. Despite beating expectations in the quarter, management raised full-year guidance only modestly due to uncertainty about whether these positive trends will continue. Investors see potential valuation upside if Centene can sustain earnings in the $6–$7 range, but recent sector volatility and unpredictable flu costs temper optimism.